Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03531255
Other study ID # APL2-307
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date August 27, 2018
Est. completion date June 2025

Study information

Verified date June 2023
Source Apellis Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study.


Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pegcetacoplan
Complement (C3) Inhibitor

See more »

Sponsors (1)

Lead Sponsor Collaborator
Apellis Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Bulgaria,  Canada,  Colombia,  France,  Germany,  Hong Kong,  Japan,  Korea, Republic of,  Malaysia,  Mexico,  Peru,  Philippines,  Russian Federation,  Serbia,  Singapore,  Spain,  Thailand,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and severity of treatment-emergent adverse events Baseline to 2 Years
See also
  Status Clinical Trial Phase
Terminated NCT04725812 - Complement Regulation to Undo Systemic Harm in Preeclampsia Phase 2
Completed NCT02598583 - Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 1/Phase 2
Recruiting NCT05539248 - A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH Phase 1/Phase 2
Active, not recruiting NCT03460301 - Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH N/A
Completed NCT01412047 - Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study N/A
Completed NCT02605993 - Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Completed NCT05095168 - Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects Phase 1
Terminated NCT04702568 - A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Completed NCT05337683 - A Retrospective Chart Review Study to Evaluate the Impact of Eculizumab in Korean PNH Patients
Not yet recruiting NCT06449001 - Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis Phase 3
Completed NCT03593200 - A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH Phase 2
Completed NCT05884060 - Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones
Available NCT05982938 - Danicopan Early Access Program